Title for MeetingAbstracts
Alphabetical listing of titles
Prostitutes, their HIV/AIDS risk behavior and the effects of health education.
Prostitutes: AIDS prevention in their private lives.
Prostitutes: their HIV/AIDS knowledge and condom use.
Prostitution and AIDS in Uruguay.
Prostitution and AIDS.
Prostitution and AIDS: results of an investigation of prostitutes' clients.
Prostitution and drugs in Spain.
Prostitution and HIV/AIDS in Uganda: A study of commercial sex workers in Kampala with emphasis on the economic gains vis-vis the health risks.
Prostitution as a consequence of sexual abuse.
Prostitution in nomadic tribes of Rajasthan in India.
Prostitution legislation as a strategy to stop the propagation of HIV/AIDS infection.
Prostitution support and information project.
Prostitution, drug use and HIV/AIDS on the streets of Albuquerque, NM, USA.
Prostitution--HIV/AIDS--profitable activities.
Prostitution: Emerging legal, ethical and human rights issues and resources.
Prostratin induces HIV reactivation and inhibits CCR5 and CXCR4 expression on PBMC.
Prostratin Induces Internalization and Degradation of HIV-specific Receptor and Co-receptor through Activation of Novel PKCs.
Protease activation during HIV infection in a CD4 positive cell line.
Protease active site-targeted anti-HIV agents containing allophenylnorstatine designed from a transition state.
Protease and Reverse Transcriptase Polymorphisms in Treatment-naive Individuals Infected with HIV-1 Subtype C in Southern Africa.
PROTEASE AND RT SEQUENCES OF B NON-B SUBTYPE HIV-1 VIRUSES FROM AMINO ACID MUTATION PATTERNS IN TREATED AN DRUG-NAIVE PATIENTS.
Protease diversity changes in HIV-1 infected individuals receiving highly active antiretroviral therapy.
Protease inhibitor (PI) change within a triple antiretroviral therapy in HIV-AIDS infected patients.
Protease inhibitor (PI) to nonnucleoside reverse transcriptase inhibitor (NNRTI) switch in an HIV infected inner city cohort.
Protease inhibitor (PI) use in women and children treated at sites of the Pediatric AIDS Clinical Trials Group (PACTG).
Protease inhibitor (PI)- and non-PI-containing antiretroviral therapy (ART) compared to no treatment in primary HIV infection (PHI).
Protease inhibitor adherence and HIV-1 RNA response.
Protease inhibitor class-sparing maintenance therapy with abacavir (ABC) + lamivudine (3TC) + zidovudine (ZDV) in patients with long-term suppression of HIV-1 RNA.
Protease inhibitor combination regimens against HIV-1 in vitro.
Protease inhibitor combination regimens against HIV-1 in vitro.